Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ixempra

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

BMS scores first oesophageal cancer nod for Opdivo in Japan

Approval in Japan comes before US okay

- PMLiVE

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Revenues down from last year but beat analyst expectations

- PMLiVE

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial

- PMLiVE

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

- PMLiVE

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

Roche Basel Switzerland

Roche builds case for SMA drug risdiplam as FDA verdict nears

Outcome of FDA review due by 24 May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links